We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





AACC 2017 Focus on CRISPR and Futuristic Testing Devices

By LabMedica International staff writers
Posted on 01 Aug 2017
Print article
At the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest exposition for clinical laboratory products and services, over 750 exhibitors displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation. But the focus was largely on clustered regularly interspaced short palindromic repeats (CRISPR), Star Trek-like testing devices, and antibiotic resistance.

Kalorama Information, (New York, NY, USA), an independent medical market research firm, estimates the market for CRISPR to be worth USD 28 billion and believes that gene editing is reaching mainstream testing. According to experts, CRISPR will be first used to treat people for blood-related diseases in a way similar to a bone marrow transplant, but to correct a person’s own blood-producing cells instead of implanting donated ones.

The 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from July 30–August 3, also featured a talk by CRISPR co-inventor Jennifer Doudna, PhD, on the future of genome engineering using this revolutionary tool, as well as a plenary on the clinical lab's critical role in combating the antibiotic resistance crisis.

Among the exhibitors at the event was Final Frontier Medical Devices, which presented its real-life Star Trek tricorder for the first time at a U.S. scientific conference. The mobile health device, named DxtER, weighs less than five pounds and allows users to monitor five real-time health vital signs and diagnose 34 diseases without the help of a clinician.

Related Links:
Kalorama Information

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)

Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.